Redox Control of Human Mitochondrial Outer Membrane Protein MitoNEET [2Fe-2S] Clusters by Biological Thiols and Hydrogen Peroxide

Received for publication, December 10, 2013, and in revised form, January 6, 2014. Published, JBC Papers in Press, January 8, 2014, DOI 10.1074/jbc.M113.542050

Aaron P. Landry and Huangen Ding

From the Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803

The human mitochondrial outer membrane protein mitoNEET is a novel target of the type II diabetes drug pioglitazone. The C-terminal cytosolic domain of mitoNEET hosts a redox-active [2Fe-2S] cluster via an unusual ligand arrangement of three cysteine residues and one histidine residue. Here we report that human mitoNEET [2Fe-2S] clusters are fully reduced when expressed in Escherichia coli cells. In vitro studies show that purified mitoNEET [2Fe-2S] clusters can be partially reduced by monothiols such as reduced glutathione, L-cysteine or the E. coli thioredoxin/thioredoxin reductase system under anaerobic conditions. Importantly, thiol-reduced mitoNEET [2Fe-2S] clusters can be reversibly oxidized by hydrogen peroxide without disruption of the clusters in vitro and in E. coli cells, indicating that mitoNEET may act as a sensor of oxidative signals to regulate mitochondrial functions via its [2Fe-2S] clusters. Furthermore, the binding of the type II diabetes drug pioglitazone in mitoNEET effectively inhibits the thiol-mediated reduction of [2Fe-2S] clusters, suggesting that pioglitazone may modulate the function of mitoNEET by blocking the thiol-mediated reduction of [2Fe-2S] clusters in the protein.

The human mitochondrial protein mitoNEET is a novel target of the type II diabetes drugs thiazolidinediones, such as pioglitazone (1). Genetic studies have shown that the deletion of mitoNEET in mice results in a reduced oxidative phosphorylation capacity in mitochondria (2). Although an increased expression of mitoNEET in adipocytes in mice enhances lipid uptake and storage and inhibits mitochondrial iron transport into the matrix, depletion of mitoNEET in adipocytes leads to less weight gain in mice (3), suggesting that mitoNEET may regulate the energy metabolism in mitochondria (1). Recent studies further indicated that mitoNEET may have a central role in neurodegenerative diseases (4, 5) and breast cancer proliferation (6) by maintaining mitochondrial homeostasis in cells.

MitoNEET localizes on mitochondrial outer membranes (2) via the N-terminal transmembrane α-helix (residues 14–32) (1). Expression of the soluble C-terminal domain (residues 33–108) of mitoNEET in Escherichia coli cells produced a protein that contains a [2Fe-2S] cluster (7). Crystallographic studies revealed that mitoNEET exists as a homodimer, with each monomer hosting a [2Fe-2S] cluster via an unusual ligand arrangement of three cysteine residues (Cys-72, Cys-74, and Cys-83) and one histidine residue (His-87) (8–10). The [2Fe-2S] clusters in mitoNEET are redox-active, with a midpoint redox potential at pH 7 ($E_{m7}$) of $0 \text{ mV}$ (11, 12). Substitution of the unique His-87 with cysteine in mitoNEET shifts $E_{m7}$ value of the [2Fe-2S] clusters from 0 to $-320 \text{ mV}$ (11) and increases the stability of the cluster in the protein (13). The redox property and stability of the [2Fe-2S] clusters in mitoNEET are also modulated by the type II diabetes drug pioglitazone (11), excess zinc (14), resveratrol-3-sulfate (15), NADPH (16), the interdomain interactions (17, 18), and the hydrogen bond network in the protein (19), suggesting that mitoNEET may act as a sensor of multiple signals to regulate mitochondrial functions (19). Interestingly, purified mitoNEET can also transfer the [2Fe-2S] clusters to apo-protein with a 50% completion time of about 120 min at room temperature (20, 21). Because mitochondria are the primary sites for iron-sulfur cluster biogenesis (22), it is appealing to consider that mitoNEET may participate in the iron-sulfur cluster biogenesis process in human cells (20, 21). Nevertheless, the iron-sulfur cluster transfer occurs only when the [2Fe-2S] clusters in mitoNEET are oxidized (20) and the cluster transfer process is inhibited by NADPH (21), suggesting that the mitoNEET-mediated iron-sulfur cluster transfer could be regulated by the redox state of the [2Fe-2S] clusters and by intracellular NADPH.

Because the cytosolic redox potential in eukaryotic cells is estimated to be around $-325 \text{ mV (pH 7.0)}$ (23), it is expected that the mitoNEET [2Fe-2S] clusters ($E_{m7} = 0 \text{ mV}$) (11, 12) would be in a reduced state in cells under physiological conditions. Nevertheless, the redox state of the mitoNEET [2Fe-2S] clusters in cells has not been demonstrated, and specific cellular components that may reduce the mitoNEET [2Fe-2S] clusters...
have not been identified. Here we report that human mitoNEET [2Fe-2S] clusters are in the fully reduced state when expressed in E. coli cells under normal growth conditions and that purified mitoNEET [2Fe-2S] clusters can be partially reduced by monothiols such as reduced glutathione, l-cysteine, and N-acetyl-l-cysteine and fully reduced by dithiothreitol and the E. coli thioredoxin-1 reduced by thioredoxin reductase and NADPH. Importantly, the reduced mitoNEET [2Fe-2S] clusters can be reversibly oxidized by hydrogen peroxide without disruption of the clusters, indicating that the redox state of the mitoNEET [2Fe-2S] clusters can be modulated by biological thiol and oxidative signals. Furthermore, we find that the type II diabetes drug pioglitazone can effectively inhibit the thiol-mediated reduction of the mitoNEET [2Fe-2S] clusters in vitro, suggesting that pioglitazone may modulate the function of mitoNEET by blocking the thiol-mediated reduction of the [2Fe-2S] clusters in the protein.

EXPERIMENTAL PROCEDURES

**Protein Purification**—The gene encoding human mitoNEET33–108 (containing amino acid residues 33–108) was cloned previously from the human cDNA library as described in Ref. 14. The mitoNEET mutant in which histidine 87 was substituted with cysteine (H87C) was constructed using the QuikChange site-directed mutagenesis kit (Stratagene). The constructed mutation was confirmed by direct sequencing (Operon Co.). Human mitoNEET and the mitoNEET mutant proteins were prepared following procedures described previously (14). E. coli thioredoxin-1 (TrxA) and thioredoxin reductase (TrxB) were produced from E. coli cells using the expression vectors pDL59 (24) and pTrR301 (25), respectively, and purified as described in Ref. 26. Both E. coli thioredoxin and thioredoxin reductase were purified as the native form. The purity of purified proteins was greater than 95%, as judged by electrophoresis analysis on a 15% polyacrylamide gel containing SDS, followed by staining with Coomassie Blue. The protein concentration of purified mitoNEET or the mitoNEET mutant H87C was measured at 280 nm using an extinction coefficient of 8.6 mM⁻¹ cm⁻¹. The protein concentration of thioredoxin-1 and thioredoxin reductase was determined at 280 nm using extinction coefficients of 14.2 and 17.7 mM⁻¹ cm⁻¹, respectively. A Beckman DU640 UV-visible spectrometer equipped with a temperature control was used for measuring absorption spectra.

**Other Chemicals**—Pioglitazone, l-cysteine, N-acetyl-l-cysteine, reduced glutathione, and other chemicals were purchased from Sigma. Isopropyl β-D-1-thiogalactopyranoside, NADPH, kanamycin, ampicillin, and dithiothreitol were from Research Product International Co. Pioglitazone was dissolved in dimethyl sulfoxide as a stock solution containing 25 mM pioglitazone. An equal amount of dimethyl sulfoxide was added to the samples as a control.

**EPR Measurements**—For whole-cell EPR measurements, E. coli cells were grown for 2 h before the recombinant protein expression was induced. After 2 h of protein expression, cells were harvested, washed once with phosphate buffer (pH 7.5), and resuspended in phosphate buffer or fresh LB medium. An aliquot (350 μl) of the E. coli cells was then transferred to the EPR tube and frozen immediately in liquid nitrogen. For the reduced samples, freshly prepared sodium dithionite was added to the E. coli cells before the EPR samples were prepared. For protein sample preparation, purified mitoNEET [2Fe-2S] clusters dissolved in buffer containing 20 mM Tris (pH 8.0) and 500 mM NaCl were purged with pure argon gas in sealed vials for 15 min before reductant was added under anaerobic conditions. After incubation at 37 °C for 20 min, samples were transferred to the EPR tubes and frozen immediately in liquid nitrogen. The X-band EPR spectra were recorded using a Bruker model ESR-300 spectrometer equipped with an Oxford Instruments 910 continuous flow cryostat. Routine EPR conditions were as follows: microwave frequency, 9.47 GHz; microwave power, 10.0 milliwatt; modulation frequency, 100 kHz; modulation amplitude, 1.2 millitelsa; temperature, 20 K; receive gain, 10⁶.

**RESULTS**

**Human MitoNEET [2Fe-2S] Clusters**

**Clones Are Fully Reduced**—Purified human mitoNEET [2Fe-2S] clusters are in an oxidized state and have no EPR signals (Fig. 1A). When purified mitoNEET [2Fe-2S] clusters are reduced with sodium dithionite (Eₓₓₓ = -600 mV (27)), a rhombic EPR spectrum with gₓ = 1.895, gᵧ = 1.937, and gₒ = 2.005 appears (Fig. 1A), as reported previously (7, 19, 28, 29). The gₓ, gᵧ, and gₒ values represent the anisotropic g-factors of a typical [2Fe-2S] cluster in proteins. In parallel, we also prepared the mitoNEET mutant H87C, in which the unique ligand His-87 of the [2Fe-2S] cluster is replaced with Cys. Although purified mitoNEET H87C has no EPR signal, addition of sodium dithionite produces a new rhombic EPR spectrum of the [2Fe-2S] cluster, with gₓ = 1.896, gᵧ = 1.970, and gₒ = 1.992, that is distinct from that of the wild-type mitoNEET (Fig. 1A).

The EPR measurement provides an efficient and non-intrusive approach to determine the redox state of iron-sulfur clusters in proteins in solutions or in whole cells (30, 31). Here, we
took the advantage of EPR to explore the redox state of the mitoNEET [2Fe-2S] clusters expressed in E. coli cells. Fig. 1B shows that E. coli cells without any recombinant proteins have very little or no EPR signals because of low concentrations of endogenous iron-sulfur proteins in cells (30, 31). Under the same experimental conditions, E. coli cells expressing human mitoNEET show a rhombic EPR signal at $g = 1.94$, which is identical to that of the reduced mitoNEET [2Fe-2S] clusters (Fig. 1A). In contrast, E. coli cells expressing the mitoNEET mutant H87C do not have any EPR signals (Fig. 1B), although both mitoNEET and the mitoNEET mutant H87C are expressed similarly in E. coli cells on the basis of SDS-PAGE gel analysis (data not shown). This is likely because the mutation of His-87 to Cys shifts the EPR signal of the mitoNEET [2Fe-2S] clusters from 0 to $-320$ mV (11). Because the cystolic redox potential of E. coli cells is about $-260$ mV (32), the mitoNEET mutant H87C [2Fe-2S] clusters would be mostly in an oxidized (EPR-silent) state in E. coli cells.

To further examine the redox state of the [2Fe-2S] clusters in wild-type mitoNEET and the mitoNEET mutant H87C expressed in E. coli cells, excess sodium dithionite is added to the cells to reduce all iron-sulfur proteins. Fig. 1C shows that addition of sodium dithionite to E. coli cells without recombinant proteins does not produce any new EPR signals. On the other hand, addition of sodium dithionite to E. coli cells expressing the mitoNEET mutant H87C generates an EPR signal at $g = 1.97$, which is the same as that of the reduced mitoNEET mutant H87C [2Fe-2S] clusters (Fig. 1A). Thus, the oxidized [2Fe-2S] clusters in the mitoNEET mutant H87C in E. coli cells can be reduced by sodium dithionite. In contrast, the EPR signal at $g = 1.94$ of the E. coli cells expressing the wild-type mitoNEET is not changed by addition of sodium dithionite, suggesting that the wild-type mitoNEET [2Fe-2S] clusters are fully reduced in E. coli cells even before the addition of sodium dithionite. Because the cystolic redox potential in eukaryotic cells ($-325$ mV (23)) is about $65$ mV lower than that in E. coli cells ($-260$ mV (32)), we postulate that the mitoNEET [2Fe-2S] clusters are most likely in a reduced state in human cells under physiological conditions.

**Human MitoNEET [2Fe-2S] Clusters Can Be Reduced by Biological Thiols**—Although it has been shown that the mitoNEET [2Fe-2S] clusters are redox-active (11, 12), specific biological molecules that can reduce or oxidize the mitoNEET [2Fe-2S] clusters are unknown. Because the mitoNEET [2Fe-2S] clusters are fully reduced in E. coli cells, we reason that the mitoNEET [2Fe-2S] clusters may be reduced by cellular reducing components that are common in both human and E. coli cells. However, NADPH is not one of them because NADPH fails to reduce the mitoNEET [2Fe-2S] clusters in vitro (21). Among other cellular reducing components, biological thiols are abundant. More importantly, biological thiols are able to form relatively stable intermediate thiol free radicals (33, 34) that can potentially provide electrons for the single-electron reduction of the oxidized [2Fe-2S] clusters in mitoNEET.

To test this idea, purified mitoNEET was incubated with thiols under anaerobic conditions. After incubation, the samples were subjected to EPR and UV-visible absorption measurements. The reduced mitoNEET [2Fe-2S] clusters were observed from the EPR signal at $g = 1.94$, and the UV-visible absorption peaks at 420 and 550 nm. As shown in Fig. 2, all biological thiols tested (reduced glutathione, l-cysteine, and N-acetyl-l-cysteine) are able to partially reduce the mitoNEET [2Fe-2S] clusters. Reduced glutathione appears to have the least ability to reduce the mitoNEET [2Fe-2S] clusters. l-Cysteine and N-acetyl-l-cysteine are able to reduce about 50% of the mitoNEET [2Fe-2S] clusters in solution under anaerobic conditions, in comparison with the fully reduced mitoNEET [2Fe-2S] clusters by sodium dithionite. A further increase of l-cysteine concentration (up to 50-fold excess over the mitoNEET [2Fe-2S] clusters) or incubation time (up to 60 min) does not increase the amount of the reduced mitoNEET [2Fe-2S] clusters in the incubation solution (data not shown), suggesting that l-cysteine could not fully reduce the mitoNEET [2Fe-2S] clusters under the experimental conditions. Interestingly, incubation with dithiothreitol, a dithiol that has an $E_{m7}$ value of $-323$ mV (35), almost fully reduced the mitoNEET [2Fe-2S] clusters under the same experimental conditions (Fig. 2).

**Human MitoNEET [2Fe-2S] Clusters Can Be Fully Reduced by the E. coli Thioredoxin/Thioredoxin Reductase System**—The biological equivalent of dithiothreitol is the ubiquitous thioredoxin (36). The $E_{m7}$ value of E. coli thioredoxin-1 is about $-270$ mV (37), which is close to that of dithiothreitol (35). To test whether the oxidized mitoNEET [2Fe-2S] clusters can be reduced by thioredoxin-1, we prepared E. coli thioredoxin-1 and thioredoxin reductase as described previously (26). When purified mitoNEET [2Fe-2S] clusters are incubated with equimolar concentrations of the E. coli thioredoxin/thioredoxin reductase or an excess amount of NADPH under anaerobic conditions, the oxidized mitoNEET [2Fe-2S] clusters are reduced to the fully reduced state.
Reduction of mitoNEET [2Fe-2S] Clusters

Previous studies have shown that iron-sulfur clusters in regulatory proteins can undergo redox transition in response to oxidative signals without disruption of the clusters (38–41). To explore whether the mitoNEET [2Fe-2S] clusters may also act as a redox sensor to oxidative signals, we examined the stability of the mitoNEET [2Fe-2S] clusters under oxidative stress conditions. Fig. 4 shows that, as the concentration of mitoNEET [2Fe-2S] clusters increases, the amount of the dithiothreitol-reduced mitoNEET [2Fe-2S] clusters remains the same before and after hydrogen peroxide treatment (Fig. 6D), suggesting that the mitoNEET [2Fe-2S] clusters can undergo redox transition in response to hydrogen peroxide without disruption of the cluster.

To further explore whether the mitoNEET [2Fe-2S] clusters could undergo redox transition in vivo in response to hydrogen peroxide, E. coli cells expressing mitoNEET [2Fe-2S] clusters were treated with hydrogen peroxide. As shown in Fig. 5, addition of hydrogen peroxide (1 mM) to the E. coli cells largely eliminates the EPR signal at g = 1.94 of the reduced mitoNEET [2Fe-2S] clusters. Reincubation of the E. coli cells in LB medium after hydrogen peroxide treatment quickly restores the EPR signal at g = 1.94 of the reduced mitoNEET [2Fe-2S] clusters, demonstrating that the mitoNEET [2Fe-2S] clusters can undergo redox transition in response to hydrogen peroxide in E. coli cells.

The Type II Diabetes Drug Pioglitazone Inhibits the Thioredoxin-Mediated Reduction of the mitoNEET [2Fe-2S] Clusters—It has been reported that binding of the type II diabetes drug pioglitazone shifts the E\textsubscript{m7} value of the mitoNEET [2Fe-2S] clusters by -100 mV (11). The negative shift of the E\textsubscript{m7} value would make it more difficult to reduce the mitoNEET [2Fe-2S] clusters. Nevertheless, how the redox state of the mitoNEET [2Fe-2S] clusters may be modulated by pioglitazone is unknown. With the finding that the mitoNEET [2Fe-2S] clusters can be reduced by biological thiols, we sought to investigate the effect of pioglitazone on the thioredoxin-mediated reduction of the mitoNEET [2Fe-2S] clusters. Purified mitoNEET is preincubated with pioglitazone, followed by reduction with thiols under anaerobic conditions. Fig. 6A shows that binding of pioglitazone had little or no effect on the dithionite-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant (E\textsubscript{m7} = -660 mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters (27). Titration experiments showed that, as the concentration of pioglitazone increased gradually in the incubation solutions (from 0 to 2.5 mM), the amount of the dithiothreitol-reduced mitoNEET [2Fe-2S] clusters was decreased progressively (Fig. 6C). We also tested whether pioglitazone affected the thioredoxin-mediated reduction of the mitoNEET [2Fe-2S] clusters in E. coli cells. As shown in Fig. 6D, binding of pioglitazone greatly inhibited the thioredoxin-mediated reduction of the mitoNEET [2Fe-2S] clusters, suggesting that pioglitazone can effectively block the biological thiol-mediated reduction of the mitoNEET [2Fe-2S] clusters in cells. Nevertheless, attempts to modulate the redox state of the mitoNEET [2Fe-2S] clusters expressed in E. coli cells with pioglitazone were not successful. This is likely because pioglitazone may not easily penetrate bacterial cell walls and/or cell membranes.

To further explore whether the mitoNEET [2Fe-2S] clusters could undergo redox transition in vivo in response to hydrogen peroxide, E. coli cells expressing mitoNEET [2Fe-2S] clusters were treated with hydrogen peroxide. As shown in Fig. 5, addition of hydrogen peroxide (1 mM) to the E. coli cells largely eliminates the EPR signal at g = 1.94 of the reduced mitoNEET [2Fe-2S] clusters. Reincubation of the E. coli cells in LB medium after hydrogen peroxide treatment quickly restores the EPR signal at g = 1.94 of the reduced mitoNEET [2Fe-2S] clusters, demonstrating that the mitoNEET [2Fe-2S] clusters can undergo redox transition in response to hydrogen peroxide in E. coli cells.

The Type II Diabetes Drug Pioglitazone Inhibits the Thioredoxin-Mediated Reduction of the mitoNEET [2Fe-2S] Clusters—It has been reported that binding of the type II diabetes drug pioglitazone shifts the $E_{m7}$ value of the mitoNEET [2Fe-2S] clusters by -100 mV (11). The negative shift of the $E_{m7}$ value would make it more difficult to reduce the mitoNEET [2Fe-2S] clusters. Nevertheless, how the redox state of the mitoNEET [2Fe-2S] clusters may be modulated by pioglitazone is unknown. With the finding that the mitoNEET [2Fe-2S] clusters can be reduced by biological thiols, we sought to investigate the effect of pioglitazone on the thioredoxin-mediated reduction of the mitoNEET [2Fe-2S] clusters. Purified mitoNEET is preincubated with pioglitazone, followed by reduction with thiols under anaerobic conditions. Fig. 6A shows that binding of pioglitazone had little or no effect on the dithionite-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters. Purified mitoNEET is preincubated with pioglitazone, followed by reduction with thiols under anaerobic conditions. Fig. 6A shows that binding of pioglitazone had little or no effect on the dithionite-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)). On the other hand, binding of pioglitazone largely inhibits the dithiothreitol-mediated reduction of the mitoNEET [2Fe-2S] clusters because dithionite is a strong reductant ($E_{m7} = -660$ mV (27)).
membranes because addition of pioglitazone to the cell extracts prepared from *E. coli* cells effectively inhibits the thiol-mediated reduction of the mitoNEET [2Fe-2S] clusters in the cell extracts (data not shown).

**DISCUSSION**

In this study, we report that human mitoNEET [2Fe-2S] clusters are fully reduced when expressed in *E. coli* cells under normal growth conditions and that the mitoNEET [2Fe-2S] clusters can be partially reduced by monothiols and fully reduced by dithiothreitol and the *E. coli* thioredoxin-1 reduced by thioredoxin reductase and NADPH *in vitro*. Importantly, the thiol-reduced mitoNEET [2Fe-2S] clusters can be reversibly oxidized by hydrogen peroxide without disruption of the clusters. Furthermore, binding of the type II diabetes drug pioglitazone effectively blocks the thiol-mediated reduction of the [2Fe-2S] clusters in cells. The possible interplay among biological thiols, hydrogen peroxide, and the type II diabetes drug pioglitazone in regulating the redox state of the mitoNEET [2Fe-2S] clusters is shown in Fig. 7.

The interaction between thioredoxin and iron-sulfur clusters in proteins has been well established in ferredoxin-thioredoxin reductase, where the reduced iron-sulfur clusters provide electrons for reduction of the oxidized thioredoxin (42, 43). However, to the best of our knowledge, the reduction of iron-sulfur clusters in proteins by biological thiols has not been reported previously. The unique ligand arrangement (Cys-72, Cys-74, Cys-83, and His-87) (8–10) and relatively high $E_m$ value (0 mV) (11, 12) may facilitate the reduction of the mitoNEET [2Fe-2S] clusters by a single mutation (His-87 to Cys) in mitoNEET shifts the $E_m$ value of the [2Fe-2S] clusters from 0 to $-320$ mV (11) and effectively prevents the reduction of the clusters by biological thiols (Fig. 3). Unlike NADPH, which fails to reduce the mitoNEET [2Fe-2S] clusters *in vitro* (21), biological thiols have a relatively stable intermediate state of thiol free radical (33, 34) that can provide electrons.

FIGURE 4. Reversible oxidation of mitoNEET [2Fe-2S] clusters by hydrogen peroxide *in vitro*. A, stability of mitoNEET (mito) [2Fe-2S] clusters in the presence of hydrogen peroxide. UV-visible absorption spectra of mitoNEET [2Fe-2S] clusters were taken after purified mitoNEET [2Fe-2S] clusters (20 µM) were incubated with hydrogen peroxide (0 to 1.0 mM). B, reversible oxidation of mitoNEET [2Fe-2S] clusters by hydrogen peroxide. UV-visible absorption spectra were taken when purified mitoNEET (20 µM) (spectrum 1) was incubated with excess dithiothreitol (10 mM) in an anaerobic cuvette at 37 °C for 20 min (spectrum 2), followed by addition of hydrogen peroxide (0.5 mM) (spectrum 3) and 14 min of additional incubation (spectrum 4). C, time course of rereduction of oxidized mitoNEET [2Fe-2S] clusters by dithiothreitol. The absorption peak at 455 nm of the oxidized mitoNEET [2Fe-2S] clusters was plotted as a function of incubation time after addition of hydrogen peroxide. D, EPR spectra of mitoNEET [2Fe-2S] clusters. Purified mitoNEET [2Fe-2S] clusters (20 µM) (spectrum 1) were reduced with dithiothreitol (10 mM) (spectrum 2), oxidized by hydrogen peroxide (0.5 mM) (spectrum 3), and rereduced after additional incubation with dithiothreitol for 14 min (spectrum 4). mT, millitesla.
for the single-electron reduction of the [2Fe-2S] clusters in mitoNEET. Interestingly, monothiols, such as reduced glutathione, l-cysteine, and N-acetyl-l-cysteine, can only partially reduce the mitoNEET [2Fe-2S] clusters, even at high concentrations and with extended incubation time. On the other hand, dithiothreitol (Fig. 2) and E. coli thioredoxin prereduced with thioredoxin reductase and NADPH (Fig. 3) can fully reduce the mitoNEET [2Fe-2S] clusters. The redox reactions underlying the reduction of the mitoNEET [2Fe-2S] clusters by biological thiols remain to be further investigated. Nevertheless, the finding that the reduced thioredoxin can reduce the mitoNEET [2Fe-2S] clusters is highly significant. Thioredoxin is highly conserved from bacteria to humans (36). In human cells, there are two major thioredoxins: thioredoxin-1, which is located in the cytosol and nucleus, and thioredoxin 2, which is located in mitochondria (44). The \( E_m \) value of human cytosolic thioredoxin-1 is about \(-230 \text{ mV} \) (pH 7.0) (45), which is close to that of E. coli thioredoxin-1 (\(-270 \text{ mV} \)) (37). Therefore, human thioredoxin-1 could be responsible for reducing the mitoNEET [2Fe-2S] clusters. Because human thioredoxin 1 has an essential role in the regulation of complex diseases, including cancer (46), cardiovascular disease, type II diabetes, and aging (47), the proposed role of human thioredoxin-1 in reducing the mitoNEET [2Fe-2S] clusters may provide fresh clues for the links between thioredoxin and various human diseases. However, it should be pointed out that other biological thiols, such as glutathione, l-cysteine, and glutaredoxins (48), may also reduce the mitoNEET [2Fe-2S] clusters in cells.

As a novel target of the type II diabetes drug pioglitazone, mitoNEET has a specific interaction with pioglitazone (1). It has been speculated that pioglitazone may modulate the energy metabolism in mitochondria via direct interaction with mitoNEET (49). Previous studies indicated that binding of pioglitazone stabilizes the [2Fe-2S] clusters in mitoNEET (10) and shifts the \( E_m \) value of the [2Fe-2S] clusters from 0 to \(-100 \text{ mV} \) (11). Here, we find that binding of pioglitazone effectively inhibits the thiol-mediated reduction of the mitoNEET [2Fe-2S] clusters, likely because of the decreased \( E_m \) value of the [2Fe-2S] clusters in the protein. Thus, pioglitazone may alter the function of mitoNEET by blocking the thiol-mediated reduction of the [2Fe-2S] clusters in cells. A set of novel ligands have been identified recently that may target mitochondrial mitoNEET (50, 51). It would be of interest to explore the effect of these ligands on the thiol-mediated reduction of the mitoNEET [2Fe-2S] clusters.

The finding that the mitoNEET [2Fe-2S] clusters can be reversibly oxidized by hydrogen peroxide without disruption of the clusters strongly suggests that the mitoNEET [2Fe-2S] cluster may act as a redox sensor to oxidative signals. The redox state of the [2Fe-2S] clusters in mitoNEET has already been attributed to regulating the iron-sulfur cluster transfer from mitoNEET to target proteins (20, 21). It would also be possible that the redox state of the [2Fe-2S] clusters may directly modulate the energy metabolism in mitochondria via specific protein-
protein interactions between mitoNEET and mitochondrial proteins, such as pyruvate dehydrogenase, in mitochondria (49). In crystal structural models, mitoNEET exists as a homodimer with two mitoNEET monomers tightly associated via the “β cap” structure (8–10). The closest distance between the two [2Fe-2S] clusters in the mitoNEET dimer is about 14 Å. We envision that, when the reduced [2Fe-2S] clusters are oxidized, two positive charges are introduced to the mitoNEET dimer. The electrostatic repulsion between the two [2Fe-2S] clusters in the mitoNEET dimer could lead to subtle conformation change and, consequently, modulate mitochondrial functions. A similar redox regulation of iron-sulfur clusters has been proposed for a number of proteins (40). For example, in the redox transcription factor SoxR, oxidation of the [2Fe-2S] clusters switches on its transcription activity (38, 41). In the bacterial DNA damage-inducible DNA helicase DinG, the enzyme is active only when the reduced [4Fe-4S] cluster is oxidized (39). In this context, we propose that mitoNEET may represent a new member of this redox signaling protein family in human cells.

A genome-wide search revealed that humans have at least two mitoNEET related proteins, Miner1 (52) and Miner2 (2), that share the conserved CDGSH domain with mitoNEET (53). Miner1 was initially localized in the endoplasmic reticulum (54), but a recent study indicated that Miner1 is mostly associated with the mitochondrial outer membrane (55). Mutations in the Miner1 gene have been attributed to Wolfram syndrome 2, a disease characterized by juvenile-onset diabetes mellitus and optic atrophy (54). Biochemical studies have shown that Miner1 interacts with BCL2 (B-cell lymphoma 2) (56) and regulates the sulfhydryl redox status, the unfolded protein response, and Ca\(^{2+}\) homeostasis in mitochondria via an unknown mechanism (57). Like mitoNEET, Miner1 hosts a [2Fe-2S] cluster via an unusual three cysteine residues and one histidine residue in its C-terminal domain (52). Although the function of Miner2 remains unknown, Miner2 is also located on the mitochondrial outer membrane and, most likely, contains a [2Fe-2S] cluster hosted by three cysteine residues and one histidine residue (2). The existence of [2Fe-2S] clusters in mitoNEET (7), Miner1 (52), and, most likely, in Miner2 (2) strongly suggests that the [2Fe-2S] clusters in this group of mitochondrial outer membrane proteins (53) may share similar and crucial regulatory functions. If the [2Fe-2S] clusters in Miner1 and Miner2, like that in mitoNEET, can be reduced by biological thiols and reversibly oxidized by hydrogen peroxide, Miner1 and Miner2 may also act as redox sensors to modulate specific functions in response to oxidative signals in human cells.

**ACKNOWLEDGMENTS**—We thank Dr. Christine Winterbourn (Christchurch School of Medicine, Christchurch, New Zealand) for advice regarding the proposed mechanisms of thiol-mediated reduction of mitoNEET [2Fe-2S] clusters.

**REFERENCES**

1. Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., and Mathews, W. R. (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. *Am. J. Physiol. Endocrinol. Metab.* **286**, F252–F260

2. Wiley, S. E., Murphy, A. N., Ross, S. A., van der Geer, P., and Dixon, J. E. (2007) MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 5318–5323

3. Kusminski, C. M., Holland, W. L., Sun, K., Park, J., Spurgin, S. B., Lin, Y., Askew, G. R., Simcox, J. A., McClain, D. A., Li, C., and Scherer, P. E. (2012) MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. *Nat. Med.* **18**, 1539–1549

4. Yonutas, H. M., and Sullivan, P. G. (2013) Targeting PPAR isoforms following CNS injury. *Curr. Drug Targets* **14**, 733–742

5. Geldenhuys, W. J., and Van der Schyf, C. J. (2013) Rationally designed multi-targeted agents against neurodegenerative diseases. *Curr. Med. Chem.* **20**, 1662–1672

6. Sohn, Y. S., Tamir, S., Song, L., Michaeli, D., Matouk, I., Conlan, A. R., Harir, Y., Holt, S. H., Shulave, V., Paddock, M. L., Hochberg, A., Cabañich, I. Z., Onuchic, J. N., Jennings, P. A., Nechushtai, R., and Mittler, R. (2013) NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 14676–14681

7. Wiley, S. E., Paddock, M. L., Abresch, E. C., Gross, L., van der Geer, P., Nechushtai, R., Murphy, A. N., Jennings, P. A., and Dixon, J. E. (2007) The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster. *J. Biol. Chem.* **282**, 23745–23749

8. Hou, X., Liu, R., Ross, S., Smart, E. J., Zhu, H., and Gong, W. (2007) Crystallographic studies of human MitoNEET. *J. Biol. Chem.* **282**, 33242–33246

9. Lin, J., Zhou, T., Ye, K., and Wang, J. (2007) Crystal structure of human mitoNEET reveals distinct groups of iron-sulfur proteins. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 14640–14645

10. Paddock, M. L., Wiley, S. E., Axelrod, H. L., Cohen, A. E., Roy, M., Abresch, E. C., Capraro, D., Murphy, A. N., Nechushtai, R., Dixon, J. E., and Jennings, P. A. (2007) MitoNEET is a uniquely folded 2Fe-2S outer mitochondrial membrane protein stabilized by pioglitazone. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 14342–14347

11. Bak, D. W., Zuris, J. A., Paddock, M. L., Jennings, P. A., and Elliott, S. J. (2009) Redox characterization of the FeS protein MitoNEET and impact of thiazolidinedione drug binding. *Biochemistry* **48**, 10193–10195

12. Tirrell, T. F., Paddock, M. L., Conlan, A. R., Smoll, E. J., Jr., Nechushtai, R., Jennings, P. A., and Kim, J. E. (2009) Resonance Raman studies of the (His)(Cys)(3) 2Fe-2S cluster of MitoNEET. Comparison to the (Cys)(4) mutant and implications of the effects of pH on the labile metal center.
Reduction of mitoNEET [2Fe-2S] Clusters

Biochemistry 48, 4747–4752
13. Conlan, A. R., Paddock, M. L., Homer, C., Axelrod, H. L., Cohen, A. E., Abresch, E. C., Zuris, J. A., Nechushtai, R., and Jennings, P. A. (2011) Mutation of the His ligand in mitoNEET stabilizes the [2Fe-2S] cluster despite conformational heterogeneity in the ligand environment. Acta Crystallogr. D. Biol. Crystallogr. 67, 516–523
14. Tan, G., Landry, A. P., Dai, R., Wang, L., Lu, J., and Ding, H. (2012) Competition of zinc ion for the [2Fe-2S] cluster binding site in the diabetes drug target protein mitoNEET. Biometals 25, 1177–1184
15. Arif, W., Xu, S., Isailovic, D., Geldenhuys, W. J., Carroll, R. T., and Funk, M. O. (2011) Complexes of the outer mitochondrial membrane protein mitoNEET with resveratrol-3-sulfate. Biochemistry 50, 5806–5811
16. Zhou, T., Lin, J., Feng, Y., and Wang, J. (2010) Binding of reduced nicotineamide adenine dinucleotide phosphate destabilizes the iron-sulfur clusters of human mitoNEET. Biochemistry 49, 9604–9612
17. Baxter, E. L., Jennings, P. A., and Onuchic, J. N. (2011) Interdomain communication revealed in the diabetes drug target mitoNEET. Proc. Natl. Acad. Sci. U.S.A. 108, 5266–5271
18. Baxter, E. L., Jennings, P. A., and Onuchic, J. N. (2012) Strand swapping regulates the iron-sulfur cluster in the diabetes drug target mitoNEET. Proc. Natl. Acad. Sci. U.S.A. 109, 1955–1960
19. Bak, D. W., and Elliott, S. J. (2013) Conserved hydrogen bonding networks of MitoNEET Tune Fe-S cluster binding and structural stability. Biochemistry 52, 4687–4696
20. Zuris, J. A., Harir, Y., Conlan, A. R., Shvartsman, M., Michaeld, D., Tamir, S., Paddock, M. L., Onuchic, J. N., Mittler, R., Cabantchik, Z. I., Jennings, P. A., and Nechushtai, R. (2011) Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein. Proc. Natl. Acad. Sci. U.S.A. 108, 13047–13052
21. Zuris, J. A., Ali, S. S., Yeh, H., Nguyen, T. A., Nechushtai, R., Paddock, M. L., and Jennings, P. A. (2012) NADPH inhibits [2Fe-2S] cluster protein transfer from diabetes drug target MitoNEET to an apo-acceptor protein. J. Biol. Chem. 287, 11649–11655
22. Veine, D. M., Mulrooney, S. B., Wang, P. F., and Williams, C. H., Jr. (1998) Formation and properties of mixed disulfides between thioredoxin reductase from Escherichia coli and thioredoxin. Evidence that cysteine-138 functions to initiate dithiol-disulfide interchange and to accept the reducing equivalent from reduced flavin. Protein Sci. 7, 1441–1450
23. Mulrooney, S. B. (1997) Application of a single-plasmid vector for multigene expression in Escherichia coli. Biochem. Pharmacol. 52, 22284–22293
24. Veine, D. M., Mulrooney, S. B., Wang, P. F., and Williams, C. H., Jr. (1998) Formation and properties of mixed disulfides between thioredoxin reductase from Escherichia coli and thioredoxin. Evidence that cysteine-138 functions to initiate dithiol-disulfide interchange and to accept the reducing equivalent from reduced flavin. Protein Sci. 7, 1441–1450
25. Mulrooney, S. B. (1997) Application of a single-plasmid vector for multigene expression in Escherichia coli. Biochem. Pharmacol. 52, 22284–22293
26. Ding, H., Harrison, K., and Lu, J. (2005) Thioredoxin reductase system mediates iron binding in IscA and iron delivery for the iron-sulfur cluster assembly in IscU. J. Biol. Chem. 280, 30432–30437
27. Mayhew, S. G. (1978) The redox potential of dithionite and SO2 from mixtures. Free Radic. Biol. Med. 40, 1889–1899
28. Szewijsk, R. P., and Whitesides, G. M. (1980) Rate constants and equilibrium constants for thiol-disulfide interchange reactions involving oxidized glutathione. J. Am. Chem. Soc. 102, 2011–2026
29. Arnér, E. S., and Holmgren, A. (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109
30. Krause, G., Lundström, J., Barea, J. L., Pueyo de la Cuesta, C., and Holmgren, A. (1991) Mimicking the active site of protein disulfide-isomerase by substitution of proline 34 in Escherichia coli thioredoxin. J. Biol. Chem. 266, 9494–9500
31. Quijano, C., Alvarez, B., Gatti, R. M., Augusto, O., and Radi, R. (1997) Pathways of peroxyxinitrite oxidation of thiol groups. Biochem. J. 322, 167–173
32. Eaton, P. (2006) Protein thiol oxidation in health and disease. Techniques for measuring disulfides and related modifications in complex protein mixtures. Free Radic. Biol. Med. 40, 1889–1899
33. Collet, J. F., and Messens, J. (2010) Structure, function, and mechanism of thioredoxin. Curr. Opin. Chem. Biol. 16, 35–44
34. Gu, M., and Inmlay, I. A. (2011) The SoxRS response of Escherichia coli is directly activated by redox-cycling drugs rather than by superoxide. Mol. Microbiol. 79, 1136–1150
35. Dai, S., Schindweinmayer, C., Schürmann, P., Ramaswamy, S., and Eklund, H. (2000) Redox signaling in chloroplasts. Cleavage of disulfides by an iron-sulfur cluster. Science 287, 655–658
36. Walters, E. M., García-Serres, R., Naik, S. G., Bourquin, F., Glauer, D. A., Schürmann, P., Huybh, B. H., and Johnson, M. K. (2009) Role of histidine-86 in the catalytic mechanism of ferredoxin:thioredoxin reductase. Biochemistry 48, 1016–1024
37. Collet, J. F., and Messens, J. (2010) Structure, function, and mechanism of thioredoxin proteins. Antioxid. Redox Signal. 13, 1205–1216
38. Watson, W. H., Pohl, J., Montfort, W. R., Stuchlik, O., Reed, M. S., Powis, G., and Jones, D. P. (2003) Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J. Biol. Chem. 278, 33408–33415
39. Wondrak, G. T. (2009) Redox-directed cancer therapeutics. Molecular mechanisms and opportunities. Antioxid. Redox Signal. 11, 3013–3069
40. Zachau, T. C., Matsushima, S., Altschined, J., Shao, D., Sadoshima, J., and Haendeler, J. (2013) Interacting with thioredoxin-1. Disease or no disease? Antioxid. Redox Signal. 18, 1053–1062
41. Hanschmann, E. M., Godoy, J. R., Berndt, C., Hudemann, C., and Lillig, C. H. (2013) Thioredoxins, glutaredoxins, and peroxidoxins–molecular mechanisms and health significance. From cofactors to antioxidants to redox signaling. Antioxid. Redox Signal. 19, 1539–1605
42. Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., and Dello Russo, C. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists. Is mitochondrial function the key? Biochem. Pharmacol. 70, 177–188
43. Geldenhuys, W. J., Funk, M. O., Awale, P. S., Lin, L., and Carroll, R. T. (2011) A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET. Bioorg. Med. Chem. Lett. 21, 5498–5501
44. Bieganowski, R. M., and Yarmush, M. L. (2011) Novel ligands that target the mitochondrial membrane protein mitoNEET. J. Mol. Graph. Model. 29, 965–973
45. Conlan, A. R., Axelrod, H. L., Cohen, A. E., Abresch, E. C., Zuris, J., Yee, D., Nechushtai, R., Jennings, P. A., and Paddock, M. L. (2009) Crystal structure of Miner1. The redox-active 2Fe-2S protein causative in Wolfram syndrome 2. J. Mol. Biol. 392, 143–153
46. Lin, J., Zhang, L., Lai, S., and Ye, K. (2011) Structure and molecular evolution of CDGS/I iron-sulfur domains. PLoS ONE 6, e24790
47. Amr, S., Heisey, C., Zhang, M., Xia, X. J., Shows, K. H., Ajlouni, K., Pandya, A., Satin, L. S., El-Shanti, H., and Shiang, R. (2007) A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am. J. Hum. Genet. 81, 673–683
55. Chen, Y. F., Kao, C. H., Chen, Y. T., Wang, C. H., Wu, C. Y., Tsai, C. Y., Liu, F. C., Yang, C. W., Wei, Y. H., Hsu, M. T., Tsai, S. F., and Tsai, T. F. (2009) Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. *Genes Dev.* **23**, 1183–1194

56. Chang, N. C., Nguyen, M., and Shore, G. C. (2012) BCL2-CISD2. An ER complex at the nexus of autophagy and calcium homeostasis. *Autophagy* **8**, 856–857

57. Wiley, S. E., Andreyev, A. Y., Divakaruni, A. S., Karisch, R., Perkins, G., Wall, E. A., van der Geer, P., Chen, Y. F., Tsai, T. F., Simon, M. I., Neel, B. G., Dixon, J. E., and Murphy, A. N. (2013) Wolfram syndrome protein, Miner1, regulates sulphhydryl redox status, the unfolded protein response, and Ca homeostasis. *EMBO Mol. Med.* **5**, 904–918